Immutep Ltd · ASX:IMM
Immutep — BIO Asia July 2020
17 slides from Immutep's conference presentation, July 2020
Slide 1: The global leader in developing LAG-3 therapeutics
The global leader in developing LAG-3 therapeutics BIO ASIA JULY 2020 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cla
Slide 3: Highlights
Highlights • Global leadership position in LAG-3 with four related product candidates in Global leader in immuno-oncology and autoimmune diseases development of LAG-3 therapeutics • Immutep’s product candidates have demonstrated clinical potential in a range of indications with high unmet need Compe
Slide 4: LAG-3 Overview - The most promising immune checkpoint
LAG-3 Overview - The most promising immune checkpoint -
Slide 5: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview Company Program Preclinical Phase I Phase II Phase III Total Trials Patients on Trials Agonist Eftilagimod Alpha Eftilagimod Alpha 4 3 22 4246 455 BMS Relatlimab 7 23 2 32 9,693 Novartis LAG525 (IMP701) 1 4 1,122 LAG525 (IMP701) 1 4 5 1,104 B.I. B.I. BI754111 BI7
Slide 6: Targeting LAG-3 / MHC II may lead to multiple therapeutics in numerous indications
Targeting LAG-3 / MHC II may lead to multiple therapeutics in numerous indications IMMUNOSTIMULATION IMMUNOSUPPRESSION Efti IMP761 APC activator Agonistic mAb APC Partnered with LAG-3 MHC II GSK’781 Partnered with Depleting mAb LAG525 T Cell Antagonistic mAb LAG-3 LAG-3 T Cell Immuno-oncology Viral
Slide 7: Immutep Controlled Immunotherapy Pipeline
Immutep Controlled Immunotherapy Pipeline* Commercial Market Size(5) Program Preclinical Phase I Phase II Late Stage(4) Rights (by) Metastatic Breast Cancer (Chemo – IO) US$12.7 billion AIPAC (2024) Non-Small-Cell Lung Carcinoma (IO – IO) (1) US$33.9 billion TACTI-002 (2026) Head and Neck Squamous C
Slide 8: Immutep Out-Licensed Immunotherapy Pipeline
Immutep Out-Licensed Immunotherapy Pipeline* Commercial Program Preclinical Phase I Phase II Late Stage(1) Rights/Partners Solid Tumors + Blood Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Oncology LAG525 Global Rights Melanoma (IO-IO-Small Molecule Combo) (Antagonist AB) § So
Slide 9: Lead Program Eftilagimod Alpha (efti or IMP321)
Lead Program Eftilagimod Alpha (efti or IMP321) - APC activation -
Slide 10: Efti: Immuno-Oncology Therapy Response Rates
Efti: Immuno-Oncology Therapy Response Rates What is the current problem: Approximately 70-80% of patients do not respond to SOC anti- PD-1 monotherapy(1) How can we enable more efficacious T-cell responses? • immunogenic cell death to liberate/uncover tumor antigens • cross-presentation of those an
Slide 11: Efti: a pipeline in a product
Efti: a pipeline in a product Efti has disruptive potential for oncology. ✓ First-in-Class MHCII agonist Trafficking of T cells to tumors (CTLs) ✓ good safety profile Priming and activation 4 ✓ encouraging efficacy data (APCs & T cells) ✓ low cost of goods 3 ✓ potential for use in various Infiltrati
Slide 12: Efti: Clinical Development TACTI-002 (Phase II)
Efti: Clinical Development TACTI-002 (Phase II) Trial Design + Introduction ➢ Phase II, multi-national, open label, Simon’s 2 stage design; PD-L1 all comer ➢ In collaboration with Merck Sharp & Dohme (MSD) Eligiblity Part A: 1st line met. NSCLC 30 mg efti SC • Available tumor + Primary: iORR (iRECIS
Slide 13: Efti: Clinical Development TACTI-mel - Results (Part A, Single Case)
Efti: Clinical Development TACTI-mel - Results (Part A, Single Case) Efficacy: Metastatic Melanoma Tumor progression Tumor regression • Patient progressing on pembrolizumab monotherapy • At 1 yr all lesions disappeared → CR (confirmed) • Patient without treatment and disease free → now lost to FU No
Slide 14: Eftilagimod Alpha Partnerships
Eftilagimod Alpha Partnerships • EOC, an Eddingpharm spin-off holding the Chinese rights for efti, Phase I study in MBC ongoing • Milestone and royalty bearing partnership • Spin off from NEC, Japan: aims to develop cancer drugs discovered by artificial intelligence → mainly cancer vaccines • Clinic
Slide 15: Immutep Outlook
Immutep Outlook
Slide 16: 2020 & 2021 Outlook and News Flow
2020 & 2021 Outlook* and News Flow Upcoming in 2020: Expected in 2021: ▪ MBC - Overall Survival data from AIPAC: ▪ Final data from TACTI-002 part A and C End of 2020 ▪ Final data from INSIGHT-004 ▪ NSCLC 1st line - more data from Stages 1 ▪ Ongoing regulatory engagement and 2 from TACTI-002 througho
Slide 17: Thank you
Thank you